Literature DB >> 912851

Clinical primary pulmonary hypertension: three pathologic types.

W D Edwards, J E Edwards.   

Abstract

Clinically, there is a group of patients with elevated pulmonary arterial pressure in whom the underlying cause is not apparent. The pulmonary arterial wedge pressure is not elevated. For such cases, the designation of primary pulmonary hypertension may be made clinically. From the clinical categorization of primary pulmonary hypertension, three distinct pathologic entities emerge, namely 1) plexogenic pulmonary arteriopathy, 2) recurrent pulmonary thromboembolism, and 3) pulmonary veno-occlusive disease. The plexogenic type is characterized initially by pulmonary arterial vasoconstriction with medial hypertrophy. Secondary proliferative intimal lesions, including the plexiform lesion, develop. Recurrent pulmonary thromboembolism is characterized by the presence of arterial thrombi of varying ages involving the microscopic-sized pulmonary arteries. Thrombi may be embolic in nature or may develop in situ. Pulmonary veno-occlusive disease is characterized by obstructive lesions of pulmonary veins and venules. The clinical presentation of the three pathologic types may be so similar that definitive diagnosis depends upon histologic examination of the lung from tissue obtained either by biopsy or at necropsy.

Entities:  

Mesh:

Year:  1977        PMID: 912851     DOI: 10.1161/01.cir.56.5.884

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

2.  Long-term follow-up in primary pulmonary hypertension.

Authors:  L D Suarez; E E Sciandro; J J Llera; A M Perosio
Journal:  Br Heart J       Date:  1979-06

3.  Primary pulmonary hypertension: modern approaches to an old problem.

Authors:  S Fein; W Frishman
Journal:  Lung       Date:  1980       Impact factor: 2.584

4.  Primary pulmonary hypertension and functional hyposplenism.

Authors:  G Fahy; K Robinson; B Deb; I Graham
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

5.  Pulmonary veno-occlusive disease: antemortem diagnosis from roentgenographic and hemodynamic findings.

Authors:  V S Rambihar; E L Fallen; J A Cairns
Journal:  Can Med Assoc J       Date:  1979-06-23       Impact factor: 8.262

6.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).

Authors:  D K Jones; T W Higenbottam; J Wallwork
Journal:  Br Heart J       Date:  1987-03

7.  Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide.

Authors:  N S Chan; J McLay; A C Kenmure
Journal:  Br Heart J       Date:  1987-02

8.  Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.

Authors:  H Saner; H P Gurtner; R Preisig; A Küpfer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Pulmonary veno-occlusive disease: diagnosis during life in four patients.

Authors:  R N Justo; A J Dare; C M Whight; D J Radford
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

10.  Indications for thrombolytic therapy in acute pulmonary embolism.

Authors:  J A Dieck; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.